Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00542178 · ClinicalTrials.gov registry record · Phase 3
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,472
- Enrollment target
NCT00542178 is a Phase 3 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 3,472 participants.
The verdict
NCT00542178, a Phase 3 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,472 participants
- Enrollment target
Study Summary
Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various treatments on cardiovascular disease in people with diabetes. This current study will examine the effects of the ACCORD treatments on the progression of DR in people participating in the ACCORD study.
Interventions
- DRUG Fenofibrate
- DRUG Hypoglycemic Agents
- DRUG Standard glycemia control
- DRUG Intensive BP treatment
- DRUG Standard BP control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,472 participants |
| Start Date | 2003-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00542178
The ClinicalTrials.gov registry entry for NCT00542178 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,472 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fenofibrate is the first listed.
NCT00542178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00542178 about?
NCT00542178 is a clinical study titled "Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)". Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various treatments on cardiovascular disease in people with diabetes. This curren...
What is the current status of trial NCT00542178?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,472 participants. The study started on 2003-10. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00542178?
The interventions under investigation include: Fenofibrate (DRUG), Hypoglycemic Agents (DRUG), Standard glycemia control (DRUG), Intensive BP treatment (DRUG), Standard BP control (DRUG).
Who is sponsoring clinical trial NCT00542178?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.